인기 연구 키워드 :
인기 활용 키워드 :

Development of aptamer-conjugated nano-liposomes for cancer-specific chemoimmunotherapy = 종양 특이적 화학면역요법을 위한 핵산 압타머 접합 나노 리포솜 개발

김민희 2023년

활용도
공유도
영향력

논문상세정보

- 저자 김민희
- 형태사항 139: 26 cm
- 일반주기 지도교수: 김동은
- 학위논문사항 생명공학과, 학위논문(박사)-, 건국대학교 대학원, 2023. 2
- 발행지 서울
- 언어 eng
- 출판년 2023
- 발행사항 건국대학교 대학원
- 주제어 Aptamer Immunotherapy Liposome Tumor microenvironment Cancertargeting Combination therapy Immunogenic cell death siRNA delivery Targeted drug-delivery
- 참고문헌( 115)
유사주제 논문( 291)

인용/피인용

Development of aptamer-conjugated nano-liposomes f ...

' Development of aptamer-conjugated nano-liposomes for cancer-specific chemoimmunotherapy = 종양 특이적 화학면역요법을 위한 핵산 압타머 접합 나노 리포솜 개발' 의 주제별 논문영향력

논문영향력 요약
동일주제 총논문수	논문피인용 총횟수	주제별 논문영향력의 평균
주제	Aptamer Immunotherapy Liposome Tumor microenvironment cancertargeting combination therapy immunogenic cell death sirna delivery targeted drug-delivery
300	0	0.0%

논문영향력
주제		주제별 논문수	주제별 논문영향력
주제어	Aptamer	31	0.0%
	Immunotherapy	132	0.0%
	Liposome	22	0.0%
	Tumor microenvironment	69	0.0%
	cancertargeting	3	0.0%
	combination therapy	33	0.0%
	immunogenic cell death	4	0.0%
	sirna delivery	3	0.0%
	targeted drug-delivery	3	0.0%
계		300	0.0%
* 다른 주제어 보유 논문에서 피인용된 횟수

' Development of aptamer-conjugated nano-liposomes for cancer-specific chemoimmunotherapy = 종양 특이적 화학면역요법을 위한 핵산 압타머 접합 나노 리포솜 개발' 의 참고문헌

[8] S. Ropero, M. Esteller. The role of histone deacetylases (HDACs) in human cancer. Mol. Oncol. 1 (2007) 19-25.
[2007]
[7] M.A. Glozak, E. Seto. Histone deacetylases and cancer. Oncogene 26 (2007) 5420- 5432.
[2007]
[6] P.A. Marks, R.A. Rifkind, V.M. Richon, R. Breslow, T. Miller, W.K. Kelly. Histone deacetylases and cancer: Causes and therapies. Nat. Rev. Cancer 1 (2001) 194-202.
[2001]
[48] A. Meireson, M. Devos, L. Brochez. IDO Expression in Cancer: Different Compartment, Different Functionality? Front. Immunol. 11 (2020) 531491.
[2020]
[47] J. Yuhan, L.Y. Zhu, L.J. Zhu, K.L. Huang, X.Y. He, W.T. Xu. Cell-specific aptamers as potential drugs in therapeutic applications: A review of current progress, J. Control. Release. 346 (2022) 405-420.
[41] C.R. Wang, X.G. Shi, H.J. Song, C.N. Zhang, X.L. Wang, P.S. Huang, et al. Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma. Biomaterials. 268 (2021) 120579.
[40] A.S. Ulrich. Biophysical aspects of using liposomes as delivery vehicles. Bioscience Rep. 22 (2002) 129-150.
[2002]
[39] M. Kim, J.S. Lee, W. Kim, J.H. Lee, B.-H. Jun, K.-S. Kim, D.-E. Kim. Aptamerconjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression. J. Control. Release 348 (2022) 893-910.
[38] D.-M. Kim, M. Kim, H.-B. Park, K.-S. Kim, D.-E. Kim. Anti-MUC1/CD44 Dual- Aptamer-Conjugated Liposomes for Cotargeting Breast Cancer Cells and Cancer Stem Cells. ACS Appl. Bio. Mater. 2 (2019) 4622-4633.
[2019]
[35] S.Z. Vahed, R. Salehi, S. Davaran, S. Sharifi. Liposome-based drug co-delivery systems in cancer cells. Mat. Sci. Eng. C-Mater. 71 (2017) 1327-1341.
[2017]
[33] A.M.M. Japir, W.D. Ke, J.J. Li, J.F. Mukerabigwi, A. Ibrahim, Y.H. Wang, X. Li, Q.H. Zhou, F. Mohammed, Z.S. Ge. Tumor-dilated polymersome nanofactories for enhanced enzyme prodrug chemo-immunotherapy. J. Control. Release. 339 (2021) 418-429.
[32] J. Nam, S. Son, K.S. Park, W. Zou, L.D. Shea, J.J. Moon. Cancer nanomedicine for combination cancer immunotherapy. Nat. Rev. Mater. 4 (2019) 398-414. Contents of this thesis (chapter 2) are same as published paper in the journal as shown below, and the format was changed to abide by thesis guideline. Minhee Kim, Keun-Sik Kim, Wooyeon Kim, Jong Hun Lee, Bong-Hyun Jun, and Dong- Eun Kim (2022) Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression. Journal of Controlled Release 348, 893-910
[32] H. Daraee, A. Etemadi, M. Kouhi, S. Alimirzalu, A. Akbarzadeh. Application of liposomes in medicine and drug delivery. Artif. Cells Nanomed. Biotechnol. 44 (2014) 381-391.
[2014]
[31] Y. Malam, M. Loizidou, A.M. Seifalian. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol. Sci. 30 (2009) 592-599.
[2009]
[29] E.A. Mohamed, Y. Zhao, M.M. Meshali, C.M. Remsberg, T.M. Borg, A.M. M. Foda, J.K. Takemoto, C.L. Sayre, S.E. Martinez, N.M. Davies, M.L. Forrest. Vorinostat with sustained exposure and high solubility in poly(ethylene glycol)‐bpoly( dl‐lactic acid) micelle nanocarriers: Characterization and effects on pharmacokinetics in rat serum and urine. J. Pharm. Sci. 101 (2012) 3787-3798.
[28] W.K. Kelly, V.M. Richon, O. O'Connor, T. Curley, B. MacGregor-Curtelli, W. Tong, M. Klang, L. Schwartz, S. Richardson, E. Rosa, M. Drobnjak, C. Cordon-Cordo, J.H. Chiao, R. Rifkind, P.A. Marks, H. Scher. Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 9 (2003) 3578-3588.
[27] X.F. Miao, Y. Zhang, Z.Y. Li, L.C. Huang, T.J. Xin, R.H. Shen, T. Wang. Inhibition of indoleamine 2,3-dioxygenase 1 synergizes with oxaliplatin for efficient colorectal cancer therapy. Mol Ther-Meth Clin D. 20 (2021) 442-450.
[27] M. Philip, A. Schietinger. CD8+ T cell differentiation and dysfunction in cancer. Nat. Rev. Immunol. 22 (2021) 209-223.
[26] K.E. Pauken, M.A. Sammons, P.M. Odorizzi, S. Manne, J. Godec, O. Khan, A.M. Drake, Z.Y. Chen, D.R. Sen, M. Kurachi, R.A. Barnitz, C. Bartman, B. Bengsch, A.C. Huang, J.M. Schenkel, G. Vahedi, W.N. Haining, S.L. Berger, E.J. Wherry. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354 (2016) 1160-1165.
[25] R. Stoltenburg, C. Reinemann, B. Strehlitz. SELEX—A (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol. Eng. 24 (2007) 381-403.
[2007]
[24] A.D. Keefe, S. Pai, A. Ellington. Aptamers as therapeutics. Nat. Rev. Drug Discov. 9 (2010) 537-550.
[2010]
[21] W.P. Zou, J.D. Wolchok, L.P. Chen. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci. Transl. Med. 8 (2016).
[2016]
[21] R. Baghba, L. Roshangar, R. Jahanban-Esfahlan, K. Seidi, A. Ebrahimi-Kalan, M. Jaymand, et al. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun. Signal. 18 (2020) 59-77.
[2020]
[19] Y. Barenholz. Doxil® — The first FDA-approved nano-drug: Lessons learned. J. Control. Release. 160 (2012) 117-134.
[2012]
[18] M.L. Immordino, F. Dosio, L. Cattel. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomed. 1 (2006) 297-315.
[2006]
[18] H.D. Dong, G.F. Zhu, K. Tamada, L.P. Chen. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5 (1999) 1365-1369.
[1999]
[17] L. Hegedűs, D. Rittler, T. Garay, P. Stockhammer, I. Kovács, B. Döme, S. Theurer, T. Hager, T. Herold, S. Kalbourtzis, A. Bankfalvi, K.W. Schmid, D. Führer, C. Aigner, B. Hegedűs. HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid Cancer Cell Line. Pathol. Oncol. Res. 26 (2020) 2523-2535.
[16] J. Majidpoor, K. Mortezaee. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives. Clin. Immunol. 226 (2021) 108707.
[15] Y. Malam, M. Loizidou, A.M. Seifalian. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends in Pharmacol Sci. 30 (2009) 592-599.
[2009]
[13] H. Zheng, W. Zhao, C. Yan, C.C. Watson, M. Massengill, M. Xie, C. Massengill, D.R. Noyes, G.V. Martinez, R. Afzal, Z. Chen, X. Ren, S.J. Antonia, E.B. Haura, B. Ruffell, A.A. Beg. HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma. Clin. Cancer Res. 22 (2016) 4119-4132.
[13] G. Gregoriadis. Carrier Potential of Liposomes in Biology and Medicine (first of two parts). N. Engl. J. Med. 295 (1976) 704-710.
[1976]
[12] G. Gregoriadis. Drug Entrapment in Liposomes. FEBS Lett. 36 (1973) 292-296.
[1973]
[12] A. Villar-Garea, M. Esteller. Histone deacetylase inhibitors: Understanding a new wave of anticancer agents. Int. J. Cancer 112 (2004) 171-178.
[2004]
[11] M.J. Peart, G.K. Smyth, R.K. van Laar, D.D. Bowtell, V.M. Richon, P.A. Marks, A.J. Holloway, R.W. Johnstone. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Pro. Natl. Acad. Sci. 102 (2005) 3697-3702.
[2005]
Up- Regulation of PD-L1 , IDO , and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
S. Spranger , R.M . Spaapen , Y. Zha , J. Williams , Y. Meng , T.T . Ha , et al . 5 ( [2013]
Understanding biophysicochemical interactions at the nano-bio interface
A.E . Nel , L. Madler , D. Velegol , T. Xia , E.M.V . Hoek , P. Somasundaran , et al . 8 ( [2009]
Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug
G. Shim , S.-E. Han , Y.-H. Yu , S. Lee , H.Y . Lee , K. Kim , I.C . Kwon , T.G . Park , Y.B . Kim , Y.S . Choi , C.-W. Kim , Y.-K. Oh . 155 ( [2011]
Trends and developments in liposome drug delivery systems
T. Lian , R.J.Y . Ho 90 ( [2001]
Toward Combination Strategies with Curative Potential
P. Sharma , J.P. Allison . Immune Checkpoint Targeting in Cancer Therapy 161 ( [2015]
The combined effects of tryptophan starvation and tryptophan catabolites downregulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells
F. Fallarino , U. Grohmann , S. You , B.C . McGrath , D.R . Cavener , C. Vacca , et al . 176 ( [2006]
The blockade of immune checkpoints in cancer immunotherapy
D.M . Pardoll 12 ( [2012]
The Epigenomics of Cancer
P.A . Jones , S.B . Baylin . 128 ( [2007]
The EPR effect : Unique features of tumor blood vessels for drug delivery , factors involved , and limitations and augmentation of the effect
J. Fang , H. Nakamura , H. Maeda 63 ( [2011]
The 1st Description of Liposomes - a Citation Classic Commentary on Diffusion of Univalent Ions across the Lamellae of Swollen Phospholipids
A. Bangham 13 ( [1965]
Targeting the IDO1 pathway in cancer : from bench to bedside
M. Liu , X. Wang , L. Wang , X.D . Ma , Z.J . Gong , S.S. Zhang , et al . 11 ( [2018]
Smart delivery of antisense oligonucleotides by anionic pH-sensitive liposomes
E. Fattal 56 ( [2004]
Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme
Triplett , K.C . Garrison , N. Marshall , M. Donkor , J. Blazeck , C. Lamb , et al . 36 ( [2018]
Regulation of Chemokines and Cytokines by Histone Deacetylases and an Update on Histone Decetylase Inhibitors in Human Diseases
H. Gatla , N. Muniraj , P. Thevkar , S. Yavvari , S. Sukhavasi , M. Makena . 20 ( [2019]
Redox- Activated Porphyrin-Based Liposome Remote-Loaded with Indoleamine 2,3- Dioxygenase ( IDO ) Inhibitor for Synergistic Photoimmunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway .
D.C. Liu , B.L . Chen , Y.L . Mo , Z.H . Wang , T. Qi , Q. Zhang , Y.G . Wang . 20 ( [2020]
RNA aptamerconjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo
S.E . Baek , K.H . Lee , Y.S . Park , D.K . Oh , S. Oh , K.S . Kim , et al 196 ( [2014]
RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo
S.E . Baek , K.H . Lee , Y.S . Park , D.-K. Oh , S. Oh , K.-S. Kim , D.-E. Kim 196 ( [2014]
Phospholipid spherules ( liposomes ) as a model for biological membranes
G. Sessa , G. Weissmann . 9 ( [1968]
PD-1 and Its Ligands in Tolerance and Immunity
M.E . Keir , M.J. Butte , G.J . Freeman , A.H. Sharpe . 26 ( [2008]
Oxaliplatin- /NLG919 prodrugs-constructed liposomes for effective chemoimmunotherapy of colorectal cancer
F.Y . Shen , L.Z . Feng , Y.J . Zhu , D.L . Tao , J. Xu , R. Peng , et al . 255 ( [2020]
Nanomedicine review : clinical developments in liposomal applications
E. Beltran-Gracia , A. Lopez-Camacho , I. Higuera-Ciapara , J.B. Velazquez- Fernandez , A.A. Vallejo-Cardona . 10 ( [2019]
Nanoenabled Reversal of IDO1-Mediated Immunosuppression Synergizes with Immunogenic Chemotherapy for Improved Cancer Therapy
H. Huang , C.T . Jiang , S. Shen , A. Liu , Y.J . Gang , Q.S . Tong , et al . 19 ( [2019]
Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression
J.Q . Lu , X.S . Liu , Y.P . Liao , F. Salazar , B.B . Sun , W. Jiang , et al . 8 ( [2017]
Molecular characteristics of immunogenic cancer cell death .
A. Tesniere , T. Panaretakis , O. Kepp , L. Apetoh , F. Ghiringhelli , L. Zitvogel , et al . 15 ( [2008]
Modulation of tumor microenvironment for immunotherapy : focus on nanomaterial-based strategies
Y. Liu , J.F . Guo , L. Huang . 10 ( [2020]
Mechanisms regulating T-cell infiltration and activity in solid tumors
E. Lanitis , D. Dangaj , M. Irving , G. Coukos . 28 ( [2017]
Magnetic nanoparticle design for medical diagnosis and therapy
S.p . Mornet , S.b . Vasseur , F. Grasset , E. Duguet . 14 ( [2004]
Liposome : classification , preparation , and applications
A. Akbarzadeh , R. Rezaei-Sadabady , S. Davaran , S.W . Joo , N. Zarghami , Y. Hanifehpour , M. Samiei , M. Kouhi , K. Nejati-Koshki . 8 ( [2013]
Liposomal drug delivery systems : From concept to clinical applications
T.M . Allen , P.R . Cullis 65 ( [2013]
Liposomal Formulations in Clinical Use : An Updated Review
U. Bulbake , S. Doppalapudi , N. Kommineni , W. Khan . 9 ( [2017]
Ligand-targeted liposome design : challenges and fundamental considerations
G.T . Noble , J.F . Stefanick , J.D . Ashley , T. Kiziltepe , B. Bilgicer . 32 ( [2014]
Intracellular delivery and antitumor effects of pH-sensitive liposomes based on zwitterionic oligopeptide lipids .
R. Mo , Q . Sun , N. Li , C. Zhang . 34 ( [2013]
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
G.C . Prendergast , C. Smith , S. Thomas , L. Mandik-Nayak , L. Laury-Kleintop , R. Metz , et al . 63 ( [2014]
Immunosuppressive Strategies that are Mediated by Tumor Cells
G.A . Rabinovich , D. Gabrilovich , E.M. Sotomayor . 25 ( [2007]
Immunogenic death of colon cancer cells treated with oxaliplatin .
A. Tesniere , F. Schlemmer , V. Boige , O. Kepp , I. Martins , F. Ghiringhelli , et al . 29 ( [2010]
Immunogenic chemotherapy : Dose and schedule dependence and combination with immunotherapy
J.J. Wu , D.J . Waxman 419 ( [2018]
Immunogenic cell death and DAMPs in cancer therapy
D.V . Krysko , A.D. Garg , A. Kaczmarek , O. Krysko , P. Agostinis , P. Vandenabeele . 12 ( [2012]
Immunogenic Cell Death in Cancer Therapy
G. Kroemer , L. Galluzzi , O. Kepp , L. Zitvogel . 31 ( [2013]
Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
A. Serrano-del Valle , A. Anel , J . Naval , I. Marzo . 7 ( [2019]
Immune Checkpoint Targeting in Cancer Therapy : Toward Combination Strategies with Curative Potential
P. Sharma , James P. Allison . 161 ( [2015]
Immune Checkpoint Blockade : A Common Denominator Approach to Cancer Therapy
S.L . Topalian , C.G . Drake , D.M . Pardoll 27 ( [2015]
Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response
J. Fucikova , P. Kralikova , A. Fialova , T. Brtnicky , L. Rob , J. Bartunkova , et al . 71 ( [2011]
Histone-deacetylase inhibitors : novel drugs for the treatment of cancer
R.W . Johnstone 1 ( [2002]
Heterochromatin and Epigenetic Control of Gene Expression
S.I.S . Grewal , D. Moazed 301 ( [2003]
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
S.C. Wei , C.R . Duffy , J.P. Allison 8 ( [2018]
Functionalizing Liposomes with anti-CD44 Aptamer for Selective Targeting of Cancer Cells
W. Alshaer , H. Hillaireau , J. Vergnaud , S. Ismail , E. Fattal . 26 ( [2014]
Functionalizing Liposomes with anti-CD44 Aptamer for Selective Targeting of Cancer Cells
W. Alshaer , H. Hillaireau , J. Vergnaud , S. Ismail , E. Fattal . 26 ( [2015]
Functionalized mesoporous silica materials for controlled drug delivery
P. Yang , S. Gai , J. Lin 41 ( [2012]
FDA Approval Summary : Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Mann , J.R. Johnson , M.H . Cohen , R. Justice , R. Pazdur 12 ( [2007]
Expression of Indoleamine 2,3-Dioxygenase Induced by IFn-gamma and TnF-alpha as Potential Biomarker of Prostate Cancer Progression
I. Banzola , C. Mengus , S. Wyler , T. Hudolin , G. Manzella , A. Chiarugi , et al . 9 ( [2018]
Exploiting the enhanced permeability and retention effect for tumor targeting .
A.K . Iyer , G. Khaled , J. Fang , H. Maeda . 11 ( [2006]
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C. Uyttenhove , L. Pilotte , I. Theate , V. Stroobant , D. Colau , N. Parmentier , et al . 9 ( [2003]
Epigenetics in cancer : Targeting chromatin modifications .
L. Ellis , P.W . Atadja , R.W . Johnstone . 8 ( [2009]
Epigenetics and gene expression .
E.R . Gibney , C.M . Nolan . 105 ( [2010]
Epigenetic regulation of gene expression : how the genome integrates intrinsic and environmental signals
R. Jaenisch , A. Bird 33 ( [2003]
Enhancing cancer immunotherapy with nanomedicine
D.J . Irvine , E.L. Dane 20 ( [2020]
Engineering precision nanoparticles for drug delivery
M.J. Mitchell , M.M . Billingsley , R.M . Haley , M.E . Wechsler , N.A . Peppas , R. Langer . 20 ( [2020]
Drug delivery and nanoparticles : Applications and hazards
W.H . De Jong , P.J.A . Borm 3 ( [2008]
Development of lipid nanoparticles for a histone deacetylases inhibitor as a promising anticancer therapeutic
T.H . Tran , D.T . Chu , D.H. Truong , J.W . Tak , J.-H. Jeong , V.L . Hoang , C.S . Yong , J.O . Kim 23 ( [2014]
Current trends and challenges in cancer management and therapy using designer nanomaterials .
P.N . Navya , A. Kaphle , S.P . Srinivas , S.K . Bhargava , V.M . Rotello , H.K . Daima 6 ( [2019]
Current Standards of Chemotherapy for Pancreatic Cancer
M.T . Saung , L. Zheng . 39 ( [2017]
Complexity : Emerging Roles in Cancer Therapy
M.A . Swartz , N. Iida , E.W . Roberts , S. Sangaletti , M.H . Wong , F.E . Yull , et al . Tumor Microenvironment 72 ( [2012]
Comparison of Drug Delivery Efficiency between Doxorubicin Intercalated in RNA Aptamer and One Encapsulated in RNA Aptamer-Conjugated Liposome
H. Park , D.-M. Kim , S.E . Baek , K.-S. Kim , D.-E. Kim 36 ( [2015]
Combinatorial Selection of DNA Thioaptamers Targeted to the HA Binding Domain of Human CD44
A. Somasunderam , V. Thiviyanathan , T. Tanaka , X. Li , M. Neerathilingam , G.L.R . Lokesh , et al . 49 ( [2010]
Combination Cancer Therapy with Immune Checkpoint Blockade : Mechanisms and Strategies
S.A. Patel , A.J . Minn 48 ( [2018]
Cold Tumors : A Therapeutic Challenge for Immunotherapy
P. Bonaventura , T. Shekarian , V. Alcazer , J. Valladeau-Guilemond , S. Valsesia- Wittmann , S. Amigorena , C. Caux , S. Depil . 10 [2019]
Cationic lipid- DNA complexes in gene delivery : from biophysics to biological applications
M.C.P . de Lima , S. Simoes , P. Pires , H. Faneca , N. Duzgunes . 47 ( [2001]
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
N. Casares , M.O . Pequignot , A. Tesniere , F. Ghiringhelli , S. Roux , N. Chaput , et al . 202 ( [2005]
Cancer immunotherapy using checkpoint blockade .
A. Ribas , J.D . Wolchok . 359 ( [2018]
Calreticulin exposure dictates the immunogenicity of cancer cell death
M. Obeid , A. Tesniere , F. Ghiringhelli , G.M . Fimia , L. Apetoh , J.L . Perfettini , et al . 13 ( [2007]
Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-gamma-induced immunologic dormancy of tumor-repopulating cells
Y.Y . Liu , X.Y . Liang , X.N . Yin , J.D . Lv , K. Tang , J.W . Ma , et al . 8 ( [2017]
Biodegradable polymeric nanoparticles based drug delivery systems
A. Kumari , S.K . Yadav , S.C. Yadav 75 ( [2010]
Binary Cooperative Prodrug Nanoparticles Improve Immunotherapy by Synergistically Modulating Immune Tumor Microenvironment
B. Feng , F.Y . Zhou , B. Hou , D.G . Wang , T.T . Wang , Y.L . Fu , Y.T . Ma , H.J . Yu , Y.P . Li 30 ( [2018]
Aptamers as targeted therapeutics : current potential and challenges
J. Zhou , J. Rossi 16 ( [2016]
Approaches to treat immune hot , altered and cold tumours with combination immunotherapies
J. Galon , D. Bruni 18 ( [2019]
Applications of Nanoparticles in Biology
M. De , P.S . Ghosh , V.M . Rotello 20 ( [2008]
Applications of Cancer Cell-Specific Aptamers in Targeted Delivery of Anticancer Therapeutic Agents
M. Kim , D.-M. Kim , K.-S. Kim , W. Jung , D.-E. Kim . 23 ( [2018]
Anticancer activities of histone deacetylase inhibitors
J.E . Bolden , M.J. Peart , R.W . Johnstone , 5 ( [2006]
Anti-MUC1/CD44 Dual- Aptamer-Conjugated Liposomes for Cotargeting Breast Cancer Cells and Cancer Stem Cells
D.M . Kim , M. Kim , H.B . Park , K.S . Kim , D.E . Kim . 2 ( [2019]
Advances and Challenges of Liposome Assisted Drug Delivery
L. Sercombe , T. Veerati , F. Moheimani , S.Y . Wu , A.K . Sood , S. Hua . 6 ( [2015]
A Novel PD-L1-targeting Antagonistic DNA Aptamer With Antitumor Effects
W.Y . Lai , B.T . Huang , J.W . Wang , P.Y . Lin , P.C . Yang . 5 ( [2016]

Development of aptamer-conjugated nano-liposomes for cancer-specific chemoimmunotherapy = 종양 특이적 화학면역요법을 위한 핵산 압타머 접합 나노 리포솜 개발

유사주제 논문( 291)

' Development of aptamer-conjugated nano-liposomes for cancer-specific chemoimmunotherapy = 종양 특이적 화학면역요법을 위한 핵산 압타머 접합 나노 리포솜 개발' 의 주제별 논문영향력

주제별 논문영향력

' Development of aptamer-conjugated nano-liposomes for cancer-specific chemoimmunotherapy = 종양 특이적 화학면역요법을 위한 핵산 압타머 접합 나노 리포솜 개발' 의 참고문헌

' Development of aptamer-conjugated nano-liposomes for cancer-specific chemoimmunotherapy = 종양 특이적 화학면역요법을 위한 핵산 압타머 접합 나노 리포솜 개발' 의 유사주제( ) 논문